Other
2029
Merck & Co. 2029 increased by 58.8% to $2.70B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.8%, from $1.70B to $2.70B. Over 5 years (FY 2020 to FY 2025), 2029 shows relatively stable performance with a 1.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
A well-distributed maturity schedule reduces the risk of liquidity crises during economic downturns.
Detailed definition
This represents the specific portion of long-term debt principal scheduled for repayment during the 2029 fiscal year, re...
Peer comparison
Similar to other large-cap peers, the company manages its debt maturity to align with long-term contract cash flows.
Metric ID:
other_long_term_debt_maturities_repayments_of_principal__8a0a63Historical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $2.30B | $1.50B | $2.10B | $1.70B | $2.70B |
| QoQ Change | — | -34.8% | +40.0% | -19.0% | +58.8% |
| YoY Change | — | -34.8% | +40.0% | -19.0% | +58.8% |
Range$1.50B – $2.70B
CAGR+17.4%
Avg YoY Growth+11.2%
Median YoY Growth+10.5%
2029 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2029?
- Merck & Co. (MRK) reported 2029 of $2.70B in Q4 2025.
- How has Merck & Co.'s 2029 changed year-over-year?
- Merck & Co.'s 2029 increased by 58.8% year-over-year, from $1.70B to $2.70B.
- What is the long-term trend for Merck & Co.'s 2029?
- Over 5 years (2020 to 2025), Merck & Co.'s 2029 has grown at a 1.6% compound annual growth rate (CAGR), from $2.50B to $2.70B.
- What does 2029 mean?
- The amount of long-term debt principal that must be repaid in 2029.